Exeltis Pharmaceuticals Holding, S.L.
Exeltis Pharmaceuticals Holding, S.L., commonly referred to as Exeltis, is a prominent player in the global pharmaceutical industry, headquartered in Spain. Founded in 2015, the company has rapidly expanded its operations across Europe, Latin America, and other key regions, focusing on innovative healthcare solutions. Specialising in women's health, dermatology, and other therapeutic areas, Exeltis is recognised for its commitment to developing unique products that address unmet medical needs. The company’s portfolio includes a range of prescription medications and over-the-counter products, distinguished by their efficacy and safety profiles. With a strong market presence, Exeltis has achieved significant milestones, including strategic partnerships and a growing international footprint, positioning itself as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Exeltis Pharmaceuticals Holding, S.L.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Exeltis Pharmaceuticals Holding, S.L.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Exeltis Pharmaceuticals Holding, S.L.'s reported carbon emissions
Exeltis Pharmaceuticals Holding, S.L., headquartered in Spain, currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no documented Scope 1, 2, or 3 emissions to report. In the absence of specific emissions data, it is important to note that Exeltis has not outlined any formal reduction targets or commitments to the Science Based Targets initiative (SBTi) or similar climate pledges. This indicates a potential area for growth in their sustainability strategy, particularly in setting measurable goals for carbon reduction and enhancing transparency regarding their environmental impact. As the pharmaceutical industry increasingly prioritises sustainability, Exeltis may benefit from establishing clear climate commitments and reduction initiatives to align with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Exeltis Pharmaceuticals Holding, S.L. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
